Study Launches Early Phase In Australia With Later Expansion To China

Founded in 2017, a China-based biotech company was pursuing innovative treatments for oncology and immunology indications. Several years after launch, the biotech outsourced full-service CRO activities to Novotech for their Health Volunteer Immunology-focused Phase I study in 2020. The following year, the sponsor awarded Novotech full-service CRO activities for a second program with a different IP; a Phase Ib /II Advanced Solid Tumors combination study.

To extend its study into China, see how the sponsor facilitated clinical development plans for Phase II component, as quickly as possible.